N.B. expands access to Paxlovid for COVID-19 patients


New Brunswick is expanding access to Paxlovid, the first approved oral antiviral treatment in Canada for COVID-19.

A release states pharmacists can now do assessments and prescribe the antiviral to anyone who has recently tested positive for COVID-19, is experiencing mild to moderate symptoms, and is at risk of severe outcomes from the virus.

Previously, New Brunswickers had to see a physician or nurse practitioner within five days of the onset of symptoms to find out if they were eligible for the treatments.

Government says the change follows a collaboration with the New Brunswick College of Pharmacists and the New Brunswick Pharmacists' Association to establish a new assessment and prescribing option for the treatment.

A list of participating pharmacies is available online.